Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | BLVRB | P30043 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554472 | 0.96 | PTGER1 (0.52) | KMOPTGER1KDM4ETTRALDH1A1 | |
| SCHEMBL16554362 | 0.86 | TSHR (0.55) | BCL2L1BADKDM4ELMNAHSD17B10 | |
| SCHEMBL30804379 | 0.85 | HSD17B14 (0.49) | PTGER1LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2555397 | 0.84 | MAPT (0.48) | PTGER1BCL2L1BADKDM4ELMNA | |
| SCHEMBL2041007 | 0.81 | RARB (0.56) | KMOLMNATTRALDH1A1PTPRC | |
| SCHEMBL29473809 | 0.81 | RARB (0.56) | KMOLMNATTRALDH1A1PTPRC | |
| SCHEMBL2560576 | 0.81 | ALDH1A1 (0.56) | PTGER1BCL2L1BADKDM4ELMNA | |
| SCHEMBL31038313 | 0.80 | CA1 (0.58) | KDM4ELMNAMAP4K4 | |
| SCHEMBL22442333 | 0.80 | ERN1 (0.52) | BCL2L1BADKDM4ELMNAHSD17B10 | |
| SCHEMBL2744832 | 0.80 | SLC22A12 (0.56) | KDM4ELMNAHSD17B10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | KMO 3110/4885EGFR 3486/4885PTGER1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.